Amyotrophic Lateral Sclerosis Pipeline - Key Players Analysis Flex Pharma, Orion Corporation, GENERVON BIOPHARMACEUTICALS LLC

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample

*NurOwn technology platform for Amyotrophic Lateral Sclerosis drug development

NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

Browse report at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

*Major companies collaborate for the development of Amyotrophic Lateral Sclerosis Pipeline

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=amyotrophic-lateral-sclerosis-pipeline-analysis

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.